Ai Viral
Freemium
Indie SaaS founders shipping with tools like Lovable or Cursor
Recensur
PaidAgentic
Investment committee prep that depends on analysts manually pulling 10-K sections, computing beta by hand, and assembling memo drafts the night before a meeting is a reliability risk dressed up as process. Recensur exists to replace that sequence with a pipeline of five specialized agents that move from SEC filing to cited committee memo without manual handoffs.
Similar tools
Ai ViralFreemiumThe tool reads your landing page URL, generates a multi-channel growth plan targeting specific…
Answer with IrisFreemiumIris picks up after-hours calls for HVAC, plumbing, electrical, and roofing contractors…
Aussie AI AgencyPaidThe service is configured and hosted by the Aussie AI Agency team, so there is no model to…
EnterviewGoPaidThe app runs locally on macOS and Windows, captures system audio only — the vendor states your…
Summary
The vendor describes a sequential five-agent architecture that ingests SEC 10-K filings, computes deterministic risk metrics including beta and VaR, runs pre-meeting position delta analysis, and produces a fully sourced investment committee memo — every claim traced back to its origin document. The deterministic risk layer is the distinguishing architectural bet: outputs are reproducible rather than stochastic, which matters when a CRO needs to defend a number in front of a board. The tool carries no API, so teams that need to pipe outputs into existing portfolio management systems or data warehouses face a manual export step. Access requires an annual contract negotiation and an institutional sandbox pilot, meaning a team cannot spin up a trial without a sales conversation — that timeline bites during an urgent research cycle.
Bottom line: Pick this for an investment committee workflow where cited, reproducible risk memos from SEC filings are the deliverable — plan a different architecture if your team needs programmatic output routing into existing portfolio systems or real-time data feeds beyond 10-K filings.
Pricing Plans
SubscriptionAnnual Contract
Custom
Institutional pricing with 20% savings on annual contracts
- Multi-agent pipeline
- Deterministic risk engine
- Cryptographic citations
- Pre-read pack delivery
View full pricing on recensur.com →
Pricing may have changed since last verified. Check the official site for current plans.
Find your fit
Before you choose Recensur
More options in Business. Compare pricing, platforms, and features side by side.
AdAnt AI
Freemium
Marketing teams running social ad campaigns
Pros
- Five-agent sequential pipeline from 10-K ingestion to committee memo, so analysts are not stitching together outputs from separate tools or rebuilding the workflow each research cycle.
- Deterministic risk metric computation — beta, VaR, and related outputs reproduce identically across runs — which means a CRO can defend a number in front of a board without qualifying it as an AI estimate.
- 100% source traceability on every claim in the generated memo, so compliance review has a direct citation path rather than requiring analysts to manually re-verify AI-generated assertions.
- Pre-meeting position delta analysis is automated inside the pipeline, so the deliverable arrives before the meeting rather than becoming a last-minute manual assembly task.
- Specialized agent architecture dedicated to institutional research artifacts, so the tool is not a general-purpose assistant being stretched to fit committee workflows — the memo format and filing scope are the product.
Cons
- No API is available, so any team that needs Recensur outputs inside a portfolio management system, data warehouse, or downstream reporting tool must export manually — at the volume of a multi-manager institutional research function, that export step becomes a recurring bottleneck and partially negates the automation argument.
- Access requires an annual contract and an institutional sandbox pilot with no self-serve trial path; teams that hit an urgent research deadline during evaluation cannot accelerate onboarding, and institutions comparing multiple vendors lose the ability to run a parallel proof-of-concept without committing to a sales process on each.
- The pipeline is scoped to SEC 10-K filings as the described input source; teams that need research synthesis across earnings call transcripts, sell-side reports, or proprietary data feeds will find the ingestion boundary a hard architectural limit — at that point, institutions with broader data requirements move toward platforms that accept arbitrary document types or offer a configurable ingestion layer.
About
- Platforms
- Web platform
- API Available
- No
- Self-Hosted
- No
- Last Updated
- September 20, 2026
Best For
Who it's for
- Investment committees
- Portfolio managers
- Chief risk officers
- Research analysts at institutions
What it does well
- Generating investment committee memos from SEC 10-K filings
- Computing deterministic risk metrics including beta and VaR
- Automating pre-meeting position delta analysis and recommendations
- Producing fully cited research with 100% source traceability
Integrations
Frequently Asked Questions
- Is Recensur free?
- Recensur is a paid tool. No permanent free tier is offered.
- What platforms does Recensur support?
- Recensur is available on: Web platform.
Manual 10-K prep creates reliability gaps
Investment committee prep that depends on analysts manually pulling 10-K sections, computing beta by hand, and assembling memo drafts the night before a meeting is a reliability risk dressed up as process. Recensur replaces that sequence with a pipeline of five specialized agents that move from SEC filing to cited committee memo without manual handoffs.
How the pipeline works
The vendor describes a sequential five-agent architecture that ingests SEC 10-K filings, computes deterministic risk metrics including beta and VaR, runs pre-meeting position delta analysis, and produces a fully sourced investment committee memo. Every claim traces back to its origin document. The deterministic risk layer produces outputs that reproduce identically across runs, which matters when a CRO needs to defend a number in front of a board.
Key limits
The tool carries no API, so teams that need to pipe outputs into existing portfolio management systems or data warehouses must export manually. Access requires an annual contract and an institutional sandbox pilot with no self-serve trial path.
Integrations and platforms
Recensur runs on a web platform and connects to SEC EDGAR, Bloomberg, Reuters, macro feeds, and earnings transcripts. Pricing follows a subscription model.
Who it is for / who should skip it
Best for investment committees, portfolio managers, chief risk officers, and research analysts at institutions that value reproducible risk numbers and full citation paths. Skip it if your team needs direct API exports or a self-serve evaluation before committing to an annual contract.
Contribute
- Work on Recensur? Claim this listing.
- Embed a badge for your README or site.
Sign in to rate this tool or suggest an edit.